Collaborating in more than 150 markets. By clicking on a link below, you may enter a different part of this website, or a website outside of Janssen.com. These sections or websites are governed by their own Legal and Privacy Policies.
Janssen Announces U.S. FDA Approval of PONVORY™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions